Email:
sales@chinesepeptide.com
Jun 22, 2019
"The 3rd China Polypeptide Industry Conference and the 2nd General Assembly of the Polypeptide Branch of China Biochemical Pharmaceutical Industry Association" was successfully concluded in Shenzhen on September 20-22, 2023! Chinese Peptide company was invited to attend the conference.
The conference will create an industry-supported, interdisciplinary integration, close integration within the industry, and linkage with the capital of the whole industry chain exchange and cooperation model, intends to invite the leaders of relevant units of national ministries and commissions, relevant drug regulatory and drug testing agencies, experts in the field of peptides, scholars, entrepreneurs, the peptide industry upstream and downstream related R & D, production, sales enterprises and researchers from universities and research institutes. Make the elite backbone of "production, university and research with management and investment" gather together for the development of China's peptide industry. The conference will have one main venue and two sub-venues, covering the directions of cutting-edge research, quality standards, production technology, clinical application and localization of the peptide industry, and exploring the realization path and countermeasures to promote the high-end climb of strategic emerging industries. During the conference, roadshow activities for the transformation of scientific and technological achievements of the peptide industry were held to promote high-quality dialogue between scientific research experts and industry enterprises.
Conference site
Dr. Shawn Lee, founder of Chinese Peptide company, was invited to participate in the third China Peptide Industry Conference and was invited to participate in the roundtable discussion: The development and future of peptide drugs, and had a warm discussion on the current development of peptide drugs with guests and audiences.
Round table discussion: Development and future of peptide drugs
Chinese Peptide company was invited to participate in the exhibition, and the on-site academic exchange was rich. During the exhibition, the exhibitors of Sino-peptide Biochemical and the guests present and colleagues in the industry had a warm discussion, and introduced the latest research progress of the company in the leading fields of polypeptide and nucleic acid CRDMO service.
Site booth map
Chinese Peptide company invited guests introduction：
Profile: Founder/Chairman of Chinese Peptide company (2001); Co-founder of Zeyue Capital (2017). Scientists and entrepreneurs from China and the United States who have successively started successful businesses, and experts in the evaluation of "National Major Special New Drugs"; Special expert of China Overseas Chinese Federation; Executive Director of Zhejiang Merchants Association; Former Vice Chairman of Xinbang Pharmaceutical [002390] (2015-2020).
Dr. Shawn Lee has founded several companies in Silicon Valley including American Peptide Co.; CPC Scientific Inc., etc. Dr. Xiang Li holds a Ph.D. in Chemistry from Chinese Academy of Sciences (1988), a postdoctoral fellow from UC Berkeley (1989), Cheung Kong Graduate School of Business (2015-2016), EMBA from IMD Business School (2015-2016), Visiting Professor at the School of Pharmacy, Pacific University, USA. "Centennial Union" Medical and Health Industry Scholar/First term (2020-2021), President of Zhejiang Haigao Association Biomedical Branch (2023-)
Founded in 2001, Chinese peptide company is a trusted global integrated peptide/nucleic acid CRDMO partner. The production base of the Chinese peptide company and the new base in the United States will simultaneously ensure the product delivery of global customers, and provide global customers with a long-term stable supply chain of peptide apis, so as to better respond to the growing customer demand.
The peptide nucleic acid business is led by national and provincial experts. Nucleic acid project covers an area of 15 acres, construction area of about 26,700 square meters, after the completion of the project will form a 10-story ground building and three-story podium of modern drug research and development and production base. Through complementary and collaborative cooperation with Chinese peptide company, the Group will eventually build a global polypeptide/nucleic acid integrated whole industry chain platform, determined to help partners more compliant, safe and efficient development of patients in urgent need of drugs, and will also provide more comprehensive services for more pharmaceutical companies around the world.
